Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ?50%: KEYNOTE-598

Basit Öğe Kaydı
dc.authoridBoyer, Michael/0000-0002-0452-2987
dc.authorwosidSendur, Mehmet Ali Nahit/H-7555-2014
dc.authorwosidBoyer, Michael/GZG-2105-2022
dc.contributor.authorBoyer, M.
dc.contributor.authorSendur, M. A. N.
dc.contributor.authorRodriguez-Abreu, D.
dc.contributor.authorPark, K.
dc.contributor.authorLee, D. H.
dc.contributor.authorCicin, I.
dc.contributor.authorYumuk, P. F.
dc.date.accessioned2024-06-12T11:12:19Z
dc.date.available2024-06-12T11:12:19Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.doi10.1016/j.jtho.2021.01.322
dc.identifier.endpageS62en_US
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue3en_US
dc.identifier.startpageS61en_US
dc.identifier.urihttps://doi.org/10.1016/j.jtho.2021.01.322
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23126
dc.identifier.volume16en_US
dc.identifier.wosWOS:000631349600006en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofJournal Of Thoracic Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPhase III Trialen_US
dc.subjectRelapsed Malignant Mesotheliomaen_US
dc.subjectImmune-Checkpoint-Inhibitoren_US
dc.titlePembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ?50%: KEYNOTE-598en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu